Stay updated with breaking news from Declan Doogan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Former FDA head Stephen Hahn is adding a new title to his role at Flagship Pioneering: CEO of the incubator's blood cancer test startup Harbinger Health. Takeda's oncology leader Rachael Brake heads to Corbus as chief scientific officer charged with redefining scope of early-stage pipeline. Goldfinch Bio snags 13-year Ardelyx vet as CSO.
/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of commercial and innovative,...
Juvenescence Debuts New Product to Aid in Supporting a Healthy Metabolism Metabolic Switch helps consumers support their healthy aging goals News provided by Share this article Share this article DOUGLAS, Isle of Man, April 15, 2021 /PRNewswire/ -- Juvenescence Ltd. (Juvenescence), a life sciences company focused on modifying aging and increasing human health span and longevity, today announced the launch of its first product. Metabolic Switch is an evidence-based, breakthrough C6 Ketone Di-ester drink that, once consumed, puts the consumer in ketosis to promote a healthy metabolism. J...
Juvenescence Limited: Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer. Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the ?rst place. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the phar...
Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, Ontario– – Portage Biotech Inc. a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence Ltd., a company … Portage may be entitled to up to USD $244 million in future milestone payments – Toronto, Ontari...